Optical Prism October 2019 | Page 25

Using the iLux® MGD Treatment System,
eye care professionals can warm the
eyelids to alleviate blocked Meibomian
glands through the application of light-
based heating. While applying the iLux®
MGD Treatment System, the practitioner
can view the eyelid margin and apply
manually-controlled compression to
express blockages, making adjustments
as needed to tailor treatment to the
individual needs of the patient. 5
Most treatments are completed in a
matter of minutes, allowing eye care
professionals to take control and treat
MGD with confidence. 6 The streamlined
nature of the treatment allows for higher
potential patient volume in dry eye clinics.
“Dry eye is a large and growing market,
and we anticipate dry eye devices to be
the fastest growing segment of the global
market through 2022,” 7
said Van Dyk. “Proactively
treating dry eye can help
establish or grow a dry eye
specialty in-clinic.”
Robust in-clinic and at-home
treatment options
The iLux® MGD Treatment System has
a natural synergy with Alcon Canada’s
market-leading SYSTANE® portfolio,
allowing Alcon to offer iLux® as an
in-office treatment and SYSTANE® as an
at-home solution for dry eye sufferers.
The SYSTANE® family of products
includes:
• SYSTANE® COMPLETE Lubricant Eye
Drops, the first all-in-one drop for all
types of dry eye.
• SYSTANE® Omega-3 Supplement, a
source of omega-3 fatty acids that
helps to relieve dry eye symptoms and
maintain good overall health. 8
• SYSTANE® Lid Wipes, Alcon Canada’s
premium, pre-moistened and
hypoallergenic eyelid cleansing wipes.
“Between crafting a personalized
treatment plan with the iLux® MGD
Treatment System and recommending
SYSTANE® COMPLETE for use at home,
I feel confident that I am providing
comprehensive dry eye therapy for my
patients,” said Dr. Parks.
Alongside the #1 doctor-recommended
SYSTANE® family of products, the iLux®
MGD Treatment System is the latest
in Alcon’s robust selection of dry eye
treatment options to help support or
develop a clinic’s dry eye practice. To
learn more, contact your Alcon Advanced
Technology Sales representative
MGD treatment system
B. Caffery et al. Prevalence of dry eye
disease in Ontario, Canada: A population-
based survey. Ocular Surface. 2019.
2
Vision Care Survey, Research Report, 2019.
This survey was conducted online by Leger,
on behalf of Alcon Canada from May 30
until June 3, 2019, among 1,500 Canadians
age 18+, using Leger’s online panel Leger
Opinion. A probability sample of the same
size would yield a margin of error +/- 2.5%,
19 times out of 20.
3
Lemp MA, Crews LA, Bron AJ, Foulks
GN, Sullivan BD. Distribution of aqueous-
1
deficient and evaporative dry eye in a clinic-
based patient cohort: a retrospective study.
Cornea. 2012;31:472-478.
4
All About Vision. Meibomian Gland
Dysfunction (MGD): The Cause Of Your
Dry Eyes? Available at: https://www.
allaboutvision.com/conditions/meibomian-
gland.htm. Accessed April 12, 2019.
5
iLux® Evaporative Dry Eye Treatment
System: User Manual. Alcon data on file.
6
Hardten DR, Schanzlin JD, Dishler JG, et al.
Comparison of a Handheld Infrared Heating
and Compression Device for Treatment
of Meibomian Gland Dysfunction to a
Thermal Pulsation Device. Presented at the
Annual Meeting of the American Society of
Cataract and Refractive Surgery (ASCRS);
April 13-17, 2018; Washington, D.C.
7
Market Scope® Charting the Course of the
Eye Care Marketing. Dry Eye Products
Report. Licensed to Alcon, Inc. Alcon data
on file. 2017.
8
Giannaccare et al.: Efficacy of Omega-3 Fatty
Acid Supplementation for Treatment of Dry
Eye Disease: A Meta-Analysis of Randomized
ClinicaTrials. Cornea 2019 (in press).
© 2019 Alcon Inc. 08/19 CA-ILU-1900028